Quick Answer
Voyager Therapeutics, Inc. reported Total Revenue of $40.37 million for fiscal year 2025.
Voyager Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $40.37M | -49.5% |
| 2024 | $80.00M | -68.0% |
| 2023 | $250.01M | +511.2% |
| 2022 | $40.91M | +9.3% |
| 2021 | $37.41M | -78.1% |
| 2020 | $171.13M | +63.9% |
| 2019 | $104.39M | +1270.1% |
| 2018 | $7.62M | -24.8% |
| 2017 | $10.13M | -28.7% |
| 2016 | $14.22M | -18.0% |
| 2015 | $17.33M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.37M | -45.7% | +157.0% |
| June 30, 2025 | $5.20M | -82.4% | -19.7% |
| March 31, 2025 | $6.47M | -66.8% | -73.7% |
| September 30, 2024 | $24.63M | +433.8% | -16.7% |
| June 30, 2024 | $29.58M | +509.5% | +51.6% |
| March 31, 2024 | $19.52M | -87.0% | +323.0% |
| September 30, 2023 | $4.61M | -88.8% | -4.9% |
| June 30, 2023 | $4.85M | +581.6% | -96.8% |
- Voyager Therapeutics, Inc. showed a decrease of -49.5% in Total Revenue compared to the prior fiscal year.
- Over the 2015–2025 period, Voyager Therapeutics, Inc.’s total revenue has grown by 132.9% (from $17.33 million to $40.37 million).
- The most recent figure is from Voyager Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: